Planta Med 2023; 89(05): 539-550
DOI: 10.1055/a-1988-2098
Biological and Pharmacological Activity
Original Papers

Pharmacological Potential of cis-jasmone in Adult Zebrafish (Danio rerio)

Francisca Magnólia Diógenes Holanda Bezerra
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Antônio Eufrásio Vieira-Neto
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Samara Casemiro Benevides
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Kaio César Simiano Tavares
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Antonia Deyse de Castro Ribeiro
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Sacha Aubrey Alves Rodrigues Santos
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Gerlânia de Oliveira Leite
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
,
Francisco Ernani Alves Magalhães
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
2   Universidade Estadual do Ceará (UECE- CECITEC), Laboratório de Bioprospecção de Produtos Naturais e Biotecnologia (LBPNB), Tauá, Ceará, Brazil
,
1   Universidade de Fortaleza, Núcleo de Biologia Experimental (NUBEX), Fortaleza, Ceará, Brazil
› Author Affiliations
Supported by: Conselho Nacional de Desenvolvimento Científico e Tecnológico
Supported by: Fundação Edson Queiroz
Supported by: Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico
Supported by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zoom Image

Abstract

This study evaluates the pharmacological potential of cis-jasmone (CJ) in adult zebrafish (Danio rerio; aZF). Initially, aZF (n = 6/group) were pretreated (20 µL; p. o.) with CJ (0.1 or 0.3 or 1.0 mg/mL) or vehicle (0.5% Tween 80). The animals were submitted to acute toxicity and locomotion tests, pentylenetetrazole-induced seizure, carrageenan-induced abdominal edema, and cinnamaldehyde-, capsaicin-, menthol-, glutamate-, and acid saline-induced orofacial nociception. The possible mechanisms of anticonvulsant, anxiolytic, and antinociceptive action were evaluated. The involvement of central afferent fibers sensitive to cinnamaldehyde and capsaicin and the effect of CJ on the relative gene expression of TRPA1 and TRPV1 in the brain of aZF were also analyzed, in addition to the study of molecular docking between CJ and TRPA1, TRPV1 channels, and GABAA receptors. CJ did not alter the locomotor behavior and showed pharmacological potential in all tested models with no toxicity. The anticonvulsant effect of CJ was prevented by flumazenil (GABAergic antagonist). The anxiolytic-like effect of CJ was prevented by flumazenil and serotonergic antagonists. The antinociceptive effect was prevented by TRPA1 and TRPV1 antagonists. Chemical ablation with capsaicin and cinnamaldehyde prevented the orofacial antinociceptive effect of CJ. Molecular docking studies indicate that CJ interacted with TRPA1, TRPV1, and GABAA receptors. CJ inhibited the relative gene expression of TRPA1 and TRPV1. CJ has pharmacological potential for the treatment of seizures, anxiety, inflammation, and acute orofacial nociception. These effects are obtained by modulating the GABAergic and serotonergic systems, as well as the TRPs and ASIC channels.



Publication History

Received: 03 March 2022

Accepted after revision: 18 November 2022

Article published online:
31 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany